- Home
- ARDX
ARDX
Ardelyx Inc.
as 04-24-2025 12:31pm EST
Ardelyx Inc is a biotechnology company focused on the discovery, development, and commercialization of innovative, first-in-class medicines that meet significant unmet medical needs. The company has a proprietary drug discovery and design platform. Its lead product candidate is tenapanor, which aims to reduce the absorption of dietary sodium and phosphorus for the treatment of kidney disease, irritable bowel syndrome with constipation, and hyperphosphatemia in patients with dialysis.
| Founded: | 2007 | Country: | United States |
| Employees: | N/A | City: | FREMONT |
| Market Cap: | 1.3B | IPO Year: | 2014 |
| Target Price: | $10.19 | AVG Volume (30 days): | 5.4M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 8 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.17 | EPS Growth: | N/A |
| 52 Week Low/High: | $4.02 - $9.33 | Next Earning Date: | 05-01-2025 |
| Revenue: | $333,615,000 | Revenue Growth: | 168.06% |
| Revenue Growth (this year): | 15.76% | Revenue Growth (next year): | 34.54% |
Stock Insider Trading Activity of Ardelyx Inc. (ARDX)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| RAAB MICHAEL | ARDX | President & CEO | Apr 4 '25 | Sell | $4.59 | 41,666 | $191,151.11 | 1,615,587 | |
| RAAB MICHAEL | ARDX | President & CEO | Mar 7 '25 | Sell | $5.36 | 41,668 | $223,198.81 | 1,615,587 | |
| MOTT DAVID M | ARDX | Director | Feb 24 '25 | Buy | $5.00 | 77,729 | $388,738.27 | 2,015,494 | |
| RAAB MICHAEL | ARDX | President & CEO | Feb 20 '25 | Sell | $5.62 | 22,964 | $129,124.28 | 1,615,587 | |
| Renz Justin A | ARDX | Chief Financial Officer | Feb 20 '25 | Sell | $5.62 | 5,171 | $29,076.53 | 285,968 | |
| Williams Laura A | ARDX | Chief Medical Officer | Feb 20 '25 | Sell | $5.62 | 4,941 | $27,783.24 | 303,804 | |
| GRAMMER ELIZABETH A | ARDX | See Remarks | Feb 20 '25 | Sell | $5.62 | 4,291 | $24,128.29 | 181,043 | |
| RAAB MICHAEL | ARDX | President & CEO | Jan 31 '25 | Sell | $5.36 | 41,666 | $223,354.76 | 1,615,587 |
Latest Ardelyx Inc. News
ARDX Breaking Stock News: Dive into ARDX Ticker-Specific Updates for Smart Investing
GlobeNewswire
5 hours ago
Ardelyx Announces Three Abstracts Accepted for Poster Presentations at Digestive Disease Week 2025 Conference
GlobeNewswire
7 days ago
Ardelyx to Report First Quarter 2025 Financial Results on May 1, 2025
Insider Monkey
8 days ago
Is Ardelyx Inc. (NASDAQ:ARDX) the Best Biotech Penny Stock to Buy According to Hedge Funds?
Simply Wall St.
8 days ago
April 2025's Top Penny Stocks To Watch
GlobeNewswire
14 days ago
Post-Hoc Analysis of the OPTIMIZE Study Supporting XPHOZAH® (tenapanor) to be Presented at the National Kidney Foundation Spring Clinical Meetings
GlobeNewswire
24 days ago
Ardelyx to Share a Post-Hoc Analysis of the OPTIMIZE Study Supporting XPHOZAH® (tenapanor) at the National Kidney Foundation Spring Clinical Meetings
GlobeNewswire
a month ago
Ardelyx Announces the First Recipients of Derek Forfang Patient Advocate Award
Simply Wall St.
a month ago
High Growth Tech Stocks In The US With Promising Potential
Compare ARDX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ARDX Ardelyx Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.